Log in

NASDAQ:NKNantkwest Stock Price, Forecast & News

-0.14 (-1.48 %)
(As of 08/13/2020 04:00 PM ET)
Today's Range
Now: $9.31
50-Day Range
MA: $12.32
52-Week Range
Now: $9.31
Volume1.99 million shs
Average Volume2.04 million shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Read More
Nantkwest logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.02 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic



Sales & Book Value

Annual Sales$40,000.00
Price / Sales25,130.02
Book Value$1.23 per share


Net Income$-65,790,000.00
Net Margins-112,350.85%


Market Cap$1.01 billion
Next Earnings Date8/18/2020 (Estimated)
-0.14 (-1.48 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nantkwest (NASDAQ:NK) Frequently Asked Questions

How has Nantkwest's stock price been impacted by Coronavirus (COVID-19)?

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NK shares have increased by 164.5% and is now trading at $9.31.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Nantkwest?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nantkwest

When is Nantkwest's next earnings date?

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, August 18th 2020.
View our earnings forecast for Nantkwest

How were Nantkwest's earnings last quarter?

Nantkwest Inc (NASDAQ:NK) announced its earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. Nantkwest had a negative return on equity of 51.94% and a negative net margin of 112,350.85%.
View Nantkwest's earnings history

What price target have analysts set for NK?

1 brokers have issued twelve-month price objectives for Nantkwest's stock. Their forecasts range from $18.00 to $18.00. On average, they expect Nantkwest's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 93.3% from the stock's current price.
View analysts' price targets for Nantkwest

Has Nantkwest been receiving favorable news coverage?

News articles about NK stock have trended positive on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nantkwest earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Nantkwest

Are investors shorting Nantkwest?

Nantkwest saw a increase in short interest in January. As of January 31st, there was short interest totaling 3,750,000 shares, an increase of 29.3% from the January 15th total of 2,900,000 shares. Based on an average trading volume of 1,980,000 shares, the short-interest ratio is presently 1.9 days. Currently, 41.0% of the company's stock are short sold.
View Nantkwest's Short Interest

Who are some of Nantkwest's key competitors?

What other stocks do shareholders of Nantkwest own?

Who are Nantkwest's key executives?

Nantkwest's management team includes the following people:
  • Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)
  • Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)
  • Mr. Richard J. Tajak, Consultant (Age 66)
  • Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)
  • Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62)

When did Nantkwest IPO?

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

What is Nantkwest's stock symbol?

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Who are Nantkwest's major shareholders?

Nantkwest's stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.18%), Meridian Investment Counsel Inc. (0.10%), California Public Employees Retirement System (0.06%), Creative Planning (0.06%), State of Wisconsin Investment Board (0.05%) and Aigen Investment Management LP (0.04%). Company insiders that own Nantkwest stock include Barry J Simon, Frederick W Driscoll, John C Thomas, Patrick Soon-Shiong and Steve Gorlin.
View institutional ownership trends for Nantkwest

Which major investors are buying Nantkwest stock?

NK stock was purchased by a variety of institutional investors in the last quarter, including Meridian Investment Counsel Inc., Bank of New York Mellon Corp, California Public Employees Retirement System, State of Wisconsin Investment Board, Aigen Investment Management LP, New York State Common Retirement Fund, Principal Financial Group Inc., and American International Group Inc..
View insider buying and selling activity for Nantkwest

How do I buy shares of Nantkwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nantkwest's stock price today?

One share of NK stock can currently be purchased for approximately $9.31.

How big of a company is Nantkwest?

Nantkwest has a market capitalization of $1.01 billion and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

What is Nantkwest's official website?

The official website for Nantkwest is www.nantkwest.com.

How can I contact Nantkwest?

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.